Predicting bacteremia in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter spog 2003 fn study

Pediatric Infectious Disease Journal

Volumn 30, Issue 7, 2011, Pages

  Agyeman, Philipp ^a   Aebi, Christoph ^a   Hirt, Andreas ^a   Niggli, Felix K ^b   Nadal, David ^b   Simon, Arne ^c   Ozsahin, Hulya ^d   Kontny, Udo ^e   Kühne, Thomas ^f   Beck Popovic, Maja ^g   Leibundgut, Kurt ^a   Bodmer, Nicole ^b   Ammann, Roland A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Bacteremia; Fever in neutropenia; Pediatric oncology; Prediction

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION RISK; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTE COUNT; VALIDATION STUDY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; INFANT; MALE; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 79959765111     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318215a290     Document Type: Article

References (42)

1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
2. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
3. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004;12:555-560.
4. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129-4134.
5. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
6. Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer. 2010 Jul 2 -Epub ahead of print—.
7. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol. 1996;14:919-924.
8. Aquino VM, Herrera L, Sandler ES, et al. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer. 2000;88:1710-1714.
9. Klaassen RJ, Goodman TR, Pham B, et al. ‘Low-risk’ prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
10. Petrilli AS, Dantas LS, Campos MC, et al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol. 2000;34:87-91.
11. Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer. 2001;92:909-913.
12. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421.
13. Alexander SW, Wade KC, Hibberd PL, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24:38-42.
14. Santolaya ME, Alvarez AM, Avilés CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis. 2002;35:678-683.
15. Ammann RA, Hirt A, Ridolfi Lüthy A, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003;41:436-443.
16. Ammann RA, Hirt A, Ridolfi Lüthy A, Aebi C. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J. 2004;23:61-67.
17. Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol. 2006;28:665-670.
18. Hakim H, Flynn PA, Srivastava DK, et al. Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2009;29:53-59.
19. Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010;28:2008-2014.
20. te Poele EM, Tissing WJ, Kamps WA, et al. Risk assessment in fever and neutropenia in children with cancer: what did we learn? Crit Rev Oncol Hematol. 2009;72:45-55.
21. Paulus S, Dobson S. Febrile neutropenia in children with cancer. Adv Exp Med Biol. 2009;634:185-204.
22. Macher E, Dubos F, Garnier N, et al. Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia. Pediatr Blood Cancer. 2010;55:662-667.
23. Oude Nijhuis C, Kamps WA, Daenen SM, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol. 2005;23:7437-7444.
24. Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer. 1996;77:791-798.
25. Koh YC, Pizzo PA. Infectious complications in pediatric cancer patients. In: Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:1190-1242.
26. Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester, United Kingdom: Wiley; 2006.
27. Altman DG. Practical Statistics for Medical Research. London, United Kingdom: Chapman & Hall; 1991.
28. Steiner I, Aebi C, Ridolfi Lüthy A, et al. Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:647-649.
29. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999;86:126-134.
30. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J. 2008;27:538-543.
31. Paganini H, Gómez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003;97:1775-1780.
32. Park JR, Coughlin J, Hawkins D, et al. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med Pediatr Oncol. 2003;40:93-98.
33. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother. 1998;41(suppl D):1-5.
34. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18:72-77.
35. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296-1304.
36. El-Maghraby SM, Moneer MM, Ismail MM, et al. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. J Pediatr Hematol Oncol. 2007;29:131-136.
37. Lehrnbecher T, Venzon D, de Haas M, et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29:414-419.
38. Kitanovski L, Jazbec J, Hojker S, et al. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis. 2006;25:413-415.
39. Stryjewski GR, Nylen ES, Bell MJ, et al. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med. 2005;6:129-135.
40. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol. 1997;99:580-588.
41. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23:7958-7966.
42. Paganini H, Aguirre C, Puppa G, et al. A prospective, multicentric scoring system to predict mortality in febrile neutropenic children with cancer. Cancer. 2007;109:2572-2579.